Cost of healthcare in the UK and world-wide continues to place an increasing burden on public finances, e.g. the 2019 NHS budget was £134 billion. There are annually 2.3 million wounds in the UK, but treatment times are long and 39% remain unhealed because existing treatments are ineffective. Wounds therefore annually cost the NHS £17.3 bn and require 278 million dressing changes; this translates into 12.9% of the entire NHS budget, 51,711 full-time nurses and 20,000 tonnes of medical waste of plastics, silicones, antimicrobials and chemicals without gaining any substantial health benefits. Furthermore, wounds result in personal costs to patients, social care costs and lost productivity. Amicapsil is an easy-to-use novel wound treatment with proven efficacy. Amicapsil and its use do not involve harmful plastics, silicones chemicals or antimicrobials. The past 2 years Willingsford has supported healthcare-professionals and private patients in the use of Amicapsil. This has gradually developed into a telemedicine approach. The project will focus on developing a telemedicine approach based on the Amicapsil that can be scaled to cover the UK and later to export. Calculations indicate that this could provide annual savings in the order of £12 billion in wound care, free up at least 40,000 nurses for other tasks, improve patients' lives and reduce costs for social care. A telemedicine approach would also provide resilience during pandemics. Furthermore, Amicapsil and its use do not involve any harmful chemicals, plastics, silicones or antimicrobials, and, with telemedicine, the need for transport would be greatly reduced. The approach would contribute strongly to the net-zero UK policy and environmental protection. The platform would also be suitable for export, creating UK jobs and tax revenues. The project will initially focus on diabetic foot ulcers (DFUs) as diabetics are particularly at risk due to Covid-19 and only 16% of infected DFUs heal within the first 12 months. In 2017, there were 174,000 DFUs in the UK costing £1.37 billion; globally there are annually over 30 million DFUs.